Intracellular progesterone receptor (PR) has been identified in human astrocytomas, the most common and aggressive primary brain tumors in humans.
Introduction
Progesterone (P4) participates in the regulation of diverse functions and diseases in the brain by interacting with its intracellular receptors (PR) [1] [2] [3] . In humans, two PR isoforms with different functions and regulation have been characterized: PR-A (94 kDa) and PR-B (116 kDa). Both isoforms are encoded by the same gene but are regulated by distinct promoters and generated from alternative transcription initiation sites [4] [5] [6] .
PR has been detected in several human brain tumors such as astrocytomas, meningiomas, chordomas and craniopharyngiomas [7] [8] [9] [10] [11] . In astrocytomas, a direct relation between PR expression and tumor grade has been reported [9, 10] , [12, 13] . The most frequent and aggressive human brain tumors are astrocytomas, which are glial cell derived tumors (gliomas) with high malignant potential. They arise from astrocytes, glial progenitor cells, or cancer stem cells [14] [15] [16] [17] [18] . They originate anywhere in the brain but are mainly located in the cerebral cortex, appearing more frequently in adults between 40 and 60 years old [19] .
Astrocytomas are classified according to their histopathological and molecular features into four grades (I-IV), where grade IV, also known as glioblastoma, represents the maximal evolution stage. The survival of patients is inversely related to the degree of tumor progression [19, 20] .
PR is expressed in biopsies from human astrocytomas [9, 12, 21] and cell lines U373 and D54 which are derived from human astrocytomas grades III and IV, respectively [19] . The content of PR increased after estradiol treatment in U373 cells [13] . In many cell types, PR expression is up-regulated by estradiol at transcriptional level by estrogen-responsive elements located in the PR promoter [22] , while P4 induces phosphorylation of PR which marks it to be degraded by the proteasome pathway resulting in a PR down-regulation [23] .
Proliferation of many cancer cells is under P4 control. P4 significantly increased the number of D54 cells from the second day of culture, and the number of U373 cells on days 3-5 whereas the PR antagonist, RU486, blocked P4 effects in both astrocytoma cell lines [21] . A transient increase in phase S of cell cycle was seen in U373 astrocytoma cells after P4 treatment, which was correlated with the induction of genes associated with cell cycle progression, such as cyclin D1 [21] , [24] . Growth factors and their receptors have been proposed as candidate mediators of P4 effects on cell proliferation. The mRNA and protein expression of vascular endothelial growth factor and epidermal growth factor receptor was increased by P4 in astrocytoma cells, and this increase was blocked by RU486 [24] . However, the effects of PR activation on the profile of gene expression in U373 cells are unknown.
Since the subcellular distribution and the expression of PR are critical for cell function, we studied PR localization by immunofluorescence as well as the gene expression pattern in U373 cells after P4 and RU486 treatments. 
Materials and Methods

Cell culture and treatments
Microarrays and analysis
TRIzol Reagent (Invitrogen, CLD, CA) was employed to isolate total RNA according manufacturer's recommendations. RNA quantity and purity was assessed by using the spectrophotometer Nanodrop-2000 (Thermo Scientific, Waltham, MA). RNA samples were tested on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) to evaluate RNA integrity. RNA samples with RIN above 9, were used to generate labeled cRNA, which were hybridized to Human The data were preprocessed and analyzed using the oligo and LIMMA (linear models for microarray data) libraries, both part of the bioconductor project, on the R statistical environment. Raw intensity data were normalized using quantile normalization. Differential expression between different groups was analyzed using empirical Bayes method implemented in the LIMMA package and P values were computed. P-value cutoff of < 0.05 and fold change cutoff of >1.5 were used as criteria to identify differences in gene expression.
RNA isolation and RT-PCR
TRIzol Reagent (Invitrogen, CLD, CA) was employed to isolate total RNA according manufacturer's recommendations. RNA quantity and purity was assessed by using the spectrophotometer Nanodrop-2000 (Thermo Scientific, MA).
RNA samples were tested on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) to evaluate RNA integrity. cDNA was synthesized from 3 μg of total RNA by using SuperScript II reverse transcription (Invitrogen CLD, CA) and oligo (dT) [12] [13] [14] [15] [16] [17] [18] Gene expression levels were normalized to those of 18S.
Statistical analysis
All images were analyzed and quantified by using Image J (Image Processing and Analysis in Java). All data were analyzed and plotted by using 
Results
Subcellular localization of PR in U373 cells
First, we determined the subcellular localization of total PR in human astrocytoma cells by immunofluorescence. We observed that PR was mainly located in the cytoplasm of U373 cells independent of hormone treatment ( Figs. 1 and 2). Estradiol increased PR presence in the cytoplasm of U373 cells that was reduced with P4 and/or RU486 treatments after estradiol PR induction ( Figs. 1 and   2 ). Experiments using P4 or RU486 alone or combining both steroids without the previous estradiol treatment were done, nevertheless, P4 and RU486 downregulated PR cytoplasmatic content in such a manner that fluorescence quantification was not possible (data not shown).
Groups of genes regulated by P4, RU486 and P4+RU486 in U373 cells
After microarray analysis, genes were organized into three groups based on the different treatments: P4, RU486 and P4+RU486 (Supplementary Tables). We
found that regulated genes encoded for proteins involved in metabolism, transport, cell cycle, proliferation, metastasis, apoptosis, processing of nucleic acids and proteins, adhesion, pathogenesis, immune response, docking complexes, cytoskeleton and membrane receptors. We also found genes encoding for siRNAs or for some products with no specific assigned function.
Validation by RT-PCR of genes regulated by P4, RU486 and P4+RU486
After the review of gene function and its exchange rate ≥ 1.5 relative to vehicle, 10 genes were chosen for microarray validation. The main criterion for choosing these genes was the fact that they have been involved in cancer development, and specifically in astrocytomas growth. In this regard, genes implicated in processes such as immune response, transcription, cytoskeletal function, metabolism, transport, proliferation, adhesion, and pathogenesis were chosen. Pseudogenes were excluded, as well as genes whose products were related to non-coding RNAs (including those which names begin with "SNOR" and "ncRNA"). The selected genes and their functions are shown in Table 2 .
In order to validate the data obtained from microarrays (Fig. 3A) , gene expression was determined by RT-PCR. In all cases the results are derived from at least three independent experiments. For mRNA expression of GLIPR2 and ANLN we did not detect significant changes after P4 treatment, however, a significant increase with RU486 treatment alone or combined with P4 was observed (Figs. 3B
and 3H). In contrast, a significant decrease in SREBF1 expression was produced by both treatments (Fig. 3D ). Regarding IL7R and HBG1 genes, we determined that P4 did not regulate their expression, but P4 together with RU486 significantly decreased it (Figs. 3C and 3I ). IL18 mRNA expression did not change after any treatment (Fig. 3E) . TGFβ2 expression increased after all treatments as compared with vehicle ( Fig. 3F ) whereas MAP1B expression decreased with all of them (3G).
STARD4 expression was increased by the combined treatment of P4 + RU486 while AOC3 gene expression was increased by P4 and P4 + RU486 (Figs. 3J and   3K ).
The effects of the different treatments in the expression of genes tested by microarray assay and RT-PCR in U373 cells are summarized in Table 3 . We observed that GLIPR2 expression evaluated by microarrays entirely coincides with that performed by RT-PCR. It is shown that in several genes such as TGFβ2, AOC3 or MAP1B, there was only one coincidence in the change observed by microarrays and RT-PCR. In other cases such as IL18, the lack of effects produced by the treatments with RU486 was observed with both methods. There was only one gene, HBG1, with no correlation observed between the results obtained by microarrays or RT-PCR (Table 3 ).
Discussion
Our study shows the cytoplasmic and nuclear distribution of PR after hormonal treatments and the regulation of the gene expression profile by P4 in U373 human astrocytoma cells. We found that total PR was principally located in the cytoplasm.
Estradiol increased the presence of PR in the cytoplasm as compared with vehicle, and the treatments with P4 and RU486 alone or combined diminished it compared to estradiol. According to this result, in a previous work our group had demonstrated by western blot that the content of both PR isoforms increased after estradiol treatment and diminished with P4 in these cells [13] . In many cell types, PR expression is up-regulated by estradiol at transcriptional level by estrogenresponsive elements located in the PR promoter [22] , while P4 induces phosphorylation of PR which marks it to be degraded by the proteasome pathway resulting in a PR down-regulation [23] . RU486 antagonizes progestins action by its binding with PR allowing dimerization and binding with DNAs hormone response elements but avoids transcription [25] . After RU486 binding, PR, phosphorylation can be induced and mark it to degradation by 26S proteasome even without transcriptional activation. Previously, it has been reported a reduction of PR isoform expression at protein level after RU486 administration in the preoptic area, uterus, ovary and breast cancer cell lines [26] [27] [28] .
In nuclei we did not find significant changes in PR content with any treatment.
In T47D breast cancer cells PR nuclear translocation occurred at 1h after progestin or RU486 treatment [29, 30] . In order to determine if this hormone or RU486 induce nuclear translocation in U373 cells we need further investigation at shorter times.
The results obtained using microarrays showed that at 12 h P4 regulates positively or negatively, the expression of various genes, many of them are and invade [31] [32] [33] . The genes whose expression was altered by P4 treatment observed in this work, are also modified by this hormone in other types of cancer and / or other pathological conditions [34] [35] [36] , however, we also determined the effect of this hormones over other genes that have not been reported before.
GLIPR2 encodes a protein still poorly studied and its function is not well characterized [37, 38] , found in many glioma cell lines and in vitro studies, this protein can induce epithelial mesenchymal transition (essential in cellular plasticity during development) and cancer progression [37, 39] IL7R is a gene whose product has a critical role in the development, differentiation, growth and activation of lymphoid cells [40] and has been associated with decreased immune response responsible for preventing the development of tumor in high grade gliomas of evolution [41] .
AOC3 gene was only modified by P4, its product is a protein which catalyzes the oxidation of amines to aldehydes but also it has been involved in cell migration and extravasation induced by inflammatory processes [42] . It should be noted that this regulation seems to be through a non-classical mechanism since the effect of P4 was not blocked by RU486. This regulation could occur through membrane PR [43] .
Interestingly, it was observed for some genes such as GLIPR2, ANLN and SREBF1 that RU486 treatment or cotreatment with P4 + RU486 regulates its expression without P4 effects. RU486 is a type II antagonist which promotes PR dimerization and allows binding of the dimers to DNA. It has been shown that RU486-bound PR-A:PR-A dimers are transcriptionally silent, whereas RU486-bound PR-B:PR-B dimers can activate transcription. RU486-bound PR-A:PR-B dimers act to distinctly inhibit transcriptional activation, and it is the activity that is commonly observed in P4 responsive cells [44, 45] . It is important to mention that in Vehicle (V); 48 h with estradiol (E) (10 nM); E followed by progesterone (P) (10 nM) for 24 h (E+P); E followed by RU486 (1 µM) for 24 h (E+RU); E followed by P+RU486 for 24 h (E+P+RU).Results are expressed as mean ± SEM; n=5. **p<0.05 vs all groups; *p<0.05 vs the other groups except V in cytoplasm. 
